Vaccine Contract Manufacturing Market Size & Share 2024 to 2032

Vaccine Contract Manufacturing Market Size

Vaccine Contract Manufacturing Market size in 2023 was valued at USD 2.7 billion and is anticipated to showcase growth at 11% from 2024 and 2032. The trend of increased outsourcing in the vaccine contract manufacturing market is primarily driven by the need for cost efficiency and specialized expertise.

Pharmaceutical and biotechnology companies are increasingly relying on contract manufacturing organizations (CMOs) to handle vaccine production due to the high costs and complexities associated with building and maintaining in-house manufacturing facilities. Further, technological advancements, such as single-use bioreactors and automation, are enhancing production efficiency and flexibility, while the rising demand for complex biologics, including mRNA vaccine and viral vector vaccines, is pushing the industry towards more innovative vaccine platforms. CMOs are expanding their production capacities and geographically diversifying their operations to better meet global demand and mitigate supply chain risks.
 

Vaccine contract manufacturing is a service provided by specialized companies, often referred to as contract manufacturing organizations (CMOs), to produce vaccines on behalf of another company, such as a pharmaceutical firm, biotech company, or government agency. This arrangement allows the contracting company to leverage the expertise, facilities, and regulatory compliance capabilities of the CMO without having to invest in its own manufacturing infrastructure.
 

Vaccine Contract Manufacturing Market Trends

• Rising demand for vaccines is significantly driving the growth of market. Public health initiatives by governments and health organizations aim to improve vaccination coverage to prevent infectious diseases, reduce healthcare costs, and enhance overall public health outcomes. Programs targeting diseases such as influenza, HPV, hepatitis, and, most notably, COVID-19 have underscored the importance of widespread vaccination, leading to heightened production needs.
   
• Furthermore, an aging global population, more susceptible to infectious diseases, increases the need for vaccines tailored to older adults, such as those for influenza, pneumococcal infections, and shingles.
   
• These factors collectively drive the demand for vaccines, compelling manufacturers to seek efficient and scalable production solutions, often through contract manufacturing organizations (CMOs) that can provide the necessary capacity and expertise.
   

Vaccine Contract Manufacturing Market Analysis

Based on vaccine type, the market is segmented into attenuated, inactivated, subunit-based, toxoid-based, and DNA-based. The attenuated segment held highest market share of 30.1% in 2023.
 

• The strong efficacy and the ability to induce both cellular and humoral immunity make attenuated vaccines a preferred choice for many infectious diseases, contributing to their dominant market share.
   
• These vaccines have a long history of successful use in preventing various diseases, including measles, mumps, rubella, polio, and yellow fever. Their proven track record has built significant trust and confidence among healthcare providers and the public.
   
• This established success facilitates regulatory approvals and widespread adoption, ensuring they remain a substantial part of vaccination programs globally.
   

Based on scale of operation, the vaccine contract manufacturing market is classified into commercial, clinical, and preclinical. The commercial segment dominated the market and was valued at USD 1.4 billion in 2023.
 

• Commercial-scale operations cater to the mass production needs of vaccines for widespread distribution and administration. Vaccines, such as those for influenza, measles, mumps, rubella, and hepatitis, require high volumes to meet global demand, driving the need for large-scale manufacturing capabilities.
   
• Companies operating at a commercial scale have extensive distribution networks and established relationships with healthcare providers, pharmacies, and government agencies worldwide. These networks facilitate efficient distribution and supply chain management, allowing vaccines to reach diverse populations effectively. Such aforementioned factors contribute to the highe market share of this segment.

Learn more about the key segments shaping this market

Download Free PDF

Based on service, the vaccine contract manufacturing market is divided into fill-finish and bulk vaccines. The fill-finish segment accounted for 57.2% of market share and is anticipated to grow at 10.8% over the forecast period.
 

• The fill-finish segment commands high market share in the market due to its critical role in ensuring the proper dosage, sterility, and stability of vaccine products.
   
• By outsourcing fill-finish services, vaccine manufacturers can mitigate operational risks, achieve cost efficiencies, and focus on core competencies such as research, development, and marketing, thereby driving the dominance of the fill-finish segment in the market.
   

Based on product type, the vaccine contract manufacturing market is categorized into combination vaccine and single vaccine. The combination vaccine segment is projected to reach USD 3.7 billion by 2032.
 

• High growth of this segment can be attributed to factors such as its efficiency, convenience, cost savings, streamlined manufacturing process, regulatory support and market preference.
   
• Furthermore, these vaccines offer expanded protection against a broader range of infectious diseases, including those with overlapping target populations or epidemiological profiles. This comprehensive protection is particularly advantageous for populations with limited access to healthcare services or in regions where multiple diseases coexist, driving the demand for combination vaccines.
   

Based on application, the vaccine contract manufacturing market is divided into human and veterinary. The human segment dominated the market in 2023 and is predicted to reach USD 6.3 billion by the end of the forecast period.
 

• Vaccines against diseases such as influenza, measles, mumps, rubella, hepatitis, and human papillomavirus (HPV) are in high demand due to their widespread prevalence and potential health impacts. Consequently, there is a continuous need to produce vaccines to prevent and control these human diseases, driving the dominance of the human segment.
   
• Furthermore, initiatives such as the Expanded Program on Immunization (EPI) by the World Health Organization (WHO) prioritize the distribution and administration of human vaccines to vulnerable populations, underscoring their importance and driving demand for contract manufacturing services.
   

Based on end-user, the vaccine contract manufacturing market is classified into pharmaceutical & biotechnology companies and academic and research institutes. The pharmaceutical & biotechnology companies segment held majority of market share in 2023 and was valued at USD 2.2 billion.
 

• Factors such as high production capacity, lower costs, and access to specialized expertise, significantly increases the adoption of contract manufacturing services by pharmaceutical & biotechnology companies.
   
• Additionally, these companies invest significantly in R&D initiatives, including vaccine discovery, preclinical testing, and clinical trials. These investments drive innovation and the development of novel vaccine candidates, creating opportunities for contract manufacturing partnerships to scale up production and bring vaccines to market efficiently.

North America vaccine contract manufacturing market in 2023 was valued at USD 1.1 billion and is expected to experience growth at 10.8% of CAGR.
 

• North America boasts a well-developed pharmaceutical industry with numerous established pharmaceutical and biotech companies that specialize in vaccine research, development, and manufacturing, driving growth of the region.
   
• The region has one of the highest healthcare expenditures globally, reflecting significant investments in healthcare infrastructure, research, and development. The region's strong healthcare spending supports vaccine development and manufacturing activities, fostering a conducive environment for contract manufacturing partnerships and investments.
   

The U.S. vaccine contract manufacturing market is expected to reach USD 2.5 billion by the end of the analysis period.
 

• The U.S. boasts a robust pharmaceutical industry with numerous leading pharmaceutical and biotech companies that specialize in vaccine research, development, and manufacturing. Furthermore, FDA's rigorous oversight and expertise in vaccine regulation provide assurance to global markets, elevating the desirability of vaccines manufactured in the U.S.
   
• Moreover, the U.S. is a global leader in vaccine development and distribution, with several vaccines developed within its borders achieving widespread international use. This leadership status, coupled with the country's reputation for innovation and quality, enhances the competitiveness of U.S.-based vaccine manufacturers in the global market.
   

Germany held a considerable share in global vaccine contract manufacturing market.
 

• With leading companies specializing in vaccine research, development, and manufacturing, Germany benefits from advanced infrastructure, skilled workforce, and regulatory expertise, positioning it as a hub for vaccine production.
   
• Additionally, its central location facilitates global distribution networks, while strong government support and investments drive innovation and competitiveness in the industry. Overall, these factors contribute to Germany's significant presence in the market.
   

India vaccine contract manufacturing market is anticipated to witness growth at substantial growth rate during the forecast period.
 

• India offers cost-effective manufacturing solutions driven by lower labor and operational costs compared to Western countries, making it an attractive destination for pharmaceutical companies seeking affordable vaccine production options.
   
• Additionally, the country's well-educated workforce, particularly in areas such as bioprocessing, quality control, and regulatory compliance, enhances its capability to meet the demand for vaccine manufacturing services. Owing to these factors India's market is poised for substantial growth during the forecast period.
   

Vaccine Contract Manufacturing Market Share

The competitive landscape of the market is characterized by the presence of several key players vying for market share. Leading pharmaceutical and biotechnology companies, contract manufacturing organizations (CMOs), and emerging players contribute to the competitive dynamics of the market.
 

Vaccine Contract Manufacturing Market Companies

Prominent players operating in the vaccine contract manufacturing industry include:

• Ajinomoto Co., Inc.
• Bavarian Nordic A/S
• Catalent, Inc
• Charles River Laboratories International Inc.
• Curia Global, Inc.
• Cytovance Biologics (Hepalink)
• Emergent BioSolutions Inc.
• Fujifilm Holdings Corporation
• Goodwin Biotechnology Inc.
• Gedeon Richter (Richter-Helm BioLogics)
• ICON PLC
• IDT Biologika GmbH
• Lonza Group AG
• Recipharm AB
• Syngene International Limited
   

Vaccine Contract Manufacturing Industry News:

• In April 2022, Moderna, Inc. announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec to support  long-term strategic partnership with the Government of Canada. This initiative helped the company to boost their manufacturing capacity and revenue.
   

The vaccine contract manufacturing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Attenuated
• Inactivated
• Subunit-based
• Toxoid-based
• DNA-based

Market, By Scale of Operation

• Commercial
• Clinical
• Preclinical

Market, By Service

• Fill-finish
• Bulk vaccines

Market, By Product Type

• Combination vaccine
• Single vaccine

Market, By Application

• Human
• Veterinary

Market, By End-user

• Pharmaceutical & biotechnology companies
• Academic and research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa